uniQure N.V.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Matthew C. Kapusta
- Full Time Employees
- 221
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Paasheuvelweg 25 Amsterdam NH Netherlands 1105 BP
- IPO Date
- Feb 5, 2014
- CIK
- 0001590560
- Website
- uniqure.com
- Similar Companies
- Business
- uniQure N.V. uniQure N.V. (NASDAQ: QURE) is a biopharmaceutical company focused on gene therapy, developing and commercializing adeno-associated virus (AAV)-based treatments for patients with severe genetic diseases including hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and cardiovascular conditions. Founded in 1998 and headquartered in Amsterdam, the Netherlands, with manufacturing in Lexington, Massachusetts, the company operates globally across the United States, Europe, and other regions, targeting rare disorders through its proprietary viral vector platform that enables potentially curative, one-time administered therapies. Its approved product, HEMGENIX (etranacogene dezaparvovec), addresses hemophilia B and is commercialized via an exclusive global licensing agreement with CSL Behring; the investigational pipeline features AMT-130 for Huntington's disease in late-stage trials with positive three-year topline data reported in 2025, AMT-260 for refractory mesial temporal lobe epilepsy with first patient dosing completed, AMT-162 for ALS, AMT-191 for Fabry disease, and cardiovascular programs in collaboration with Bristol Myers Squibb. Recent developments include a September 2025 refinancing of $50 million debt into a $175 million non-dilutive senior secured term loan facility with Hercules Capital, Inc., extending maturity to 2030 and providing up to $125 million additional funding tied to AMT-130 regulatory and financial milestones to support a potential 2026 U.S. commercial launch; third quarter 2025 financial results highlighted pipeline progress; and ongoing strategic partnerships such as the 2021 CSL Behring deal involving $500 million in payments and a 2023 royalty rights sale for up to $400 million to HealthCare Royalty and Sagard Healthcare.
Company News
QURE Submits Application for Gene Therapy for Huntington's Disease
15 Stocks to Watch With Short Squeeze Potential
uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says
uniQure seeks US approval for Huntington's gene therapy after FDA reversal
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Disease
Why Is uniQure (QURE) Up 17.5% Since Last Earnings Report?
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Bloom Energy, Dave, Fiverr, Humana, Las Vegas Sands, Lemonade, Procter & Gamble, SK hynix, Wix.com, and More
uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript
uniQure Q2 Earnings Call Highlights
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
uniQure to Announce Second Quarter 2026 Financial Results
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
uniQure (QURE) Now Trades Above Golden Cross: Time to Buy?
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
uniQure Announces Pricing of Upsized $225 Million Public Offering